Neutralizing antibodies and fusion inhibitory peptides
have the
potential required to combat the global pandemic caused by SARS-CoV-2
and its variants. However, the lack of oral bioavailability and enzymatic
susceptibility limited their application, necessitating the development
of novel pan-CoV fusion inhibitors. Herein we report a series of helical
peptidomimetics, d-sulfonyl-γ-AApeptides, which effectively
mimic the key residues of heptad repeat 2 and interact with heptad
repeat 1 in the SARS-CoV-2 S2 subunit, resulting in inhibiting SARS-CoV-2
spike protein-mediated fusion between virus and cell membranes. The
leads also displayed broad-spectrum inhibitory activity against a
panel of other human CoVs and showed strong potency in vitro and in vivo. Meanwhile, they also demonstrated
complete resistance to proteolytic enzymes or human sera and exhibited
extremely long half-life in vivo and highly promising
oral bioavailability, delineating their potential as pan-CoV fusion
inhibitors with the potential to combat SARS-CoV-2 and its variants.